mk8931 Search Results


hy  (MedChemExpress)
93
MedChemExpress hy
Hy, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy/product/MedChemExpress
Average 93 stars, based on 1 article reviews
hy - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
verubecestat t7011  (TargetMol)
90
TargetMol verubecestat t7011
Verubecestat T7011, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/verubecestat t7011/product/TargetMol
Average 90 stars, based on 1 article reviews
verubecestat t7011 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
verubecestat (mk-8931  (Merck & Co)
90
Merck & Co verubecestat (mk-8931
Current clinical status of amyloid-related DMTs strategies, tau-related DMTs strategies and DMTs of other mechanisms.
Verubecestat (Mk 8931, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/verubecestat (mk-8931/product/Merck & Co
Average 90 stars, based on 1 article reviews
verubecestat (mk-8931 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
bace1 inhibitor mk-8931  (Forum pharmaceuticals)
90
Forum pharmaceuticals bace1 inhibitor mk-8931
<t>BACE1</t> inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).
Bace1 Inhibitor Mk 8931, supplied by Forum pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bace1 inhibitor mk-8931/product/Forum pharmaceuticals
Average 90 stars, based on 1 article reviews
bace1 inhibitor mk-8931 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mk8931  (Merck & Co)
90
Merck & Co mk8931
<t>BACE1</t> inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).
Mk8931, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mk8931/product/Merck & Co
Average 90 stars, based on 1 article reviews
mk8931 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
verubecestat (mk-8931)  (MedKoo Inc)
90
MedKoo Inc verubecestat (mk-8931)
<t>BACE1</t> inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).
Verubecestat (Mk 8931), supplied by MedKoo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/verubecestat (mk-8931)/product/MedKoo Inc
Average 90 stars, based on 1 article reviews
verubecestat (mk-8931) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
verubecestat (mk-8931)  (Albany Molecular Research)
90
Albany Molecular Research verubecestat (mk-8931)
<t>BACE1</t> inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).
Verubecestat (Mk 8931), supplied by Albany Molecular Research, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/verubecestat (mk-8931)/product/Albany Molecular Research
Average 90 stars, based on 1 article reviews
verubecestat (mk-8931) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
protease inhibitors verubecestat mk-8931  (ApexBio)
90
ApexBio protease inhibitors verubecestat mk-8931
<t>BACE1</t> inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).
Protease Inhibitors Verubecestat Mk 8931, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protease inhibitors verubecestat mk-8931/product/ApexBio
Average 90 stars, based on 1 article reviews
protease inhibitors verubecestat mk-8931 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mk-8931  (Eisai Inc)
90
Eisai Inc mk-8931
<t>BACE1</t> inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).
Mk 8931, supplied by Eisai Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mk-8931/product/Eisai Inc
Average 90 stars, based on 1 article reviews
mk-8931 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mk-8931  (Schering-Plough corporation)
90
Schering-Plough corporation mk-8931
<t>BACE1</t> inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).
Mk 8931, supplied by Schering-Plough corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mk-8931/product/Schering-Plough corporation
Average 90 stars, based on 1 article reviews
mk-8931 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
verubecestat (mk-8931) trifluoroacetat  (Aladdin Scientific Corporation)
N/A
InformationVerubecestat (MK-8931) Trifluoroacetat Verubecestat (MK-8931) Trifluoroacetat is a potent and selective beta-secretase inhibitor and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor.TargetsBACE2 (Cell-free assay); BACE1 (Cell-free assay) 0.37 nM(Ki); 1.75 nM(Ki)In vitroVerubecestat(MK-8931) effectively reduces
   Buy from Supplier
verubecestat (mk-8931)  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier

Image Search Results


Current clinical status of amyloid-related DMTs strategies, tau-related DMTs strategies and DMTs of other mechanisms.

Journal: Frontiers in Aging Neuroscience

Article Title: Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics

doi: 10.3389/fnagi.2024.1429211

Figure Lengend Snippet: Current clinical status of amyloid-related DMTs strategies, tau-related DMTs strategies and DMTs of other mechanisms.

Article Snippet: Verubecestat (MK-8931) , • BACE inhibitors • To assess MK-8931’s safety and effectiveness in prodromal AD patients with amnestic MCI , NCT01953601 , Merck Sharp & Dohme LLC , Phase 3 , Terminated (2019).

Techniques: Formulation, Functional Assay, Adjuvant, Injection, Biomarker Assay, Mutagenesis, Derivative Assay

BACE1 inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).

Journal: Frontiers in Aging Neuroscience

Article Title: BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines

doi: 10.3389/fnagi.2018.00229

Figure Lengend Snippet: BACE1 inhibitor MK-8931 altered plasticity of dendritic spines in vivo . (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over 21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test results: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from two-way ANOVA (day 0–28).

Article Snippet: The BACE1 inhibitor MK-8931 was synthesized following the schemes provided by FORUM Pharmaceuticals (Waltham, MA, USA) and formulated in 10% (w/v) 2-hydroxypropyl-beta-cyclodextrin.

Techniques: In Vivo, Labeling, Imaging

MK-8931 treatment did not cause spine elimination. (A) Spine stability and turnover rates in vehicle and MK-8931 treated mice. Daily turnover rate significantly decreased at the end of inhibitor treatment. (B,C) MK-8931 treatment significantly decreased density of transient spines, whereas density of stable spines was not affected. Bonferroni post-hoc test: ns: p = 0.4926, * p < 0.05, *** p < 0.001, **** p < 0.0001 (two-way ANOVA between day 0–28). (D) Survival rate of newly gained spines was not affected by BACE1 inhibitor treatment. N = 5 animals per group, n = 10 dendrites per animal. Two-tailed Student’s t -test, t (8) = 0.9, p = 0.394. Data presented as mean ± SEM.

Journal: Frontiers in Aging Neuroscience

Article Title: BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines

doi: 10.3389/fnagi.2018.00229

Figure Lengend Snippet: MK-8931 treatment did not cause spine elimination. (A) Spine stability and turnover rates in vehicle and MK-8931 treated mice. Daily turnover rate significantly decreased at the end of inhibitor treatment. (B,C) MK-8931 treatment significantly decreased density of transient spines, whereas density of stable spines was not affected. Bonferroni post-hoc test: ns: p = 0.4926, * p < 0.05, *** p < 0.001, **** p < 0.0001 (two-way ANOVA between day 0–28). (D) Survival rate of newly gained spines was not affected by BACE1 inhibitor treatment. N = 5 animals per group, n = 10 dendrites per animal. Two-tailed Student’s t -test, t (8) = 0.9, p = 0.394. Data presented as mean ± SEM.

Article Snippet: The BACE1 inhibitor MK-8931 was synthesized following the schemes provided by FORUM Pharmaceuticals (Waltham, MA, USA) and formulated in 10% (w/v) 2-hydroxypropyl-beta-cyclodextrin.

Techniques: Two Tailed Test